|
US10865245B2
(en)
|
2014-12-23 |
2020-12-15 |
Full Spectrum Genetics, Inc. |
Anti-B7H3 binding compounds and uses thereof
|
|
WO2016106004A1
(en)
*
|
2014-12-23 |
2016-06-30 |
Full Spectrum Genetics, Inc. |
Novel anti-b7h3 binding compounds and uses thereof
|
|
US11071788B2
(en)
*
|
2015-06-23 |
2021-07-27 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
US20190300606A1
(en)
*
|
2016-07-01 |
2019-10-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibitory Immune Receptor Inhibition Methods and Compositions
|
|
CA3050085A1
(en)
|
2017-01-20 |
2018-07-26 |
Juno Therapeutics Gmbh |
Cell surface conjugates and related cell compositions and methods
|
|
CN109843927B
(zh)
*
|
2017-03-06 |
2022-06-21 |
江苏恒瑞医药股份有限公司 |
抗b7-h3抗体、其抗原结合片段及其医药用途
|
|
UA125593C2
(uk)
|
2017-03-31 |
2022-04-27 |
Джянгсу Хенгруй Медісін Ко., Лтд. |
Антитіло в7-н3, його антигензв'язуючий фрагмент та його медичне застосування
|
|
WO2018191438A1
(en)
|
2017-04-11 |
2018-10-18 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
EA201992683A1
(ru)
*
|
2017-05-12 |
2020-04-23 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Применение антител против b7h3 для лечения злокачественных опухолей в центральной нервной системе
|
|
CN109963591B
(zh)
*
|
2017-08-04 |
2023-04-04 |
江苏恒瑞医药股份有限公司 |
B7h3抗体-药物偶联物及其医药用途
|
|
WO2019032628A1
(en)
|
2017-08-07 |
2019-02-14 |
The Regents Of The University Of California |
GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
|
|
CA3073227A1
(en)
|
2017-08-17 |
2019-02-21 |
Michael D. Miller |
Firearm assembly system and method
|
|
WO2019051102A2
(en)
|
2017-09-08 |
2019-03-14 |
Maverick Therapeutics, Inc. |
Constrained conditionally activated binding proteins
|
|
EP3700938A1
(en)
*
|
2017-10-26 |
2020-09-02 |
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. |
Novel recombinant fusion proteins, preparation and use thereof
|
|
WO2019086507A1
(en)
|
2017-10-31 |
2019-05-09 |
Pantarhei Bioscience B.V. |
Immunotherapeutic methods for treating and/or preventing lung cancer
|
|
CN109939231A
(zh)
*
|
2017-12-21 |
2019-06-28 |
张曼 |
关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用
|
|
CN109939126A
(zh)
*
|
2017-12-21 |
2019-06-28 |
张曼 |
Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用
|
|
KR102839330B1
(ko)
|
2018-01-15 |
2025-07-30 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-1에 대한 단일-도메인 항체 및 이의 변이체
|
|
CN111868083B
(zh)
|
2018-01-15 |
2025-02-11 |
桑昆血液供给基金会 |
因子h增强抗体及其用途
|
|
IL277863B2
(en)
|
2018-04-11 |
2026-02-01 |
Inhibrx Inc |
Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
|
|
WO2019225787A1
(ko)
*
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
MA52889A
(fr)
|
2018-06-15 |
2021-04-21 |
Flagship Pioneering Innovations V Inc |
Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
|
|
WO2020018964A1
(en)
|
2018-07-20 |
2020-01-23 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for controlled expression of antigen-specific receptors
|
|
CA3105891A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
WO2020041626A1
(en)
*
|
2018-08-23 |
2020-02-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Affibody proteins specific for b7-h3 (cd276)
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CA3115082A1
(en)
*
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
AU2018449846B2
(en)
*
|
2018-11-22 |
2023-12-14 |
Beijing Kanova Biopharmaceutical Co., Ltd. |
An anti-B7-H3 antibody
|
|
WO2020181140A1
(en)
|
2019-03-05 |
2020-09-10 |
Maverick Therapeutics, Inc. |
Constrained conditionally activated binding proteins
|
|
CN109929039A
(zh)
*
|
2019-03-28 |
2019-06-25 |
郑州大学第一附属医院 |
基于cd276抗体的嵌合抗原受体、慢病毒表达载体及其应用
|
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
|
BR112021022682A2
(pt)
|
2019-05-14 |
2022-02-22 |
Provention Bio Inc |
Métodos e composições para prevenir diabetes do tipo 1
|
|
WO2020238926A1
(en)
*
|
2019-05-28 |
2020-12-03 |
Single Cell Technology, Inc. |
Anti-b7-h3 antibodies
|
|
JP2022537672A
(ja)
*
|
2019-07-03 |
2022-08-29 |
クリスタル バイオサイエンス インコーポレイテッド |
抗ｂ７－ｈ３抗体およびその使用方法
|
|
KR102732027B1
(ko)
*
|
2019-07-09 |
2024-11-20 |
주식회사 와이바이오로직스 |
B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
|
|
US11820814B2
(en)
|
2019-07-17 |
2023-11-21 |
Gemini Therapeutics Sub, Inc. |
Factor H potentiating antibodies and uses thereof
|
|
WO2021037319A1
(en)
|
2019-08-30 |
2021-03-04 |
Y-Mabs Therapeutics, Inc. |
Immunohistochemical assessment of b7-h3 expression
|
|
CN110642948B
(zh)
*
|
2019-10-09 |
2021-06-29 |
达石药业(广东)有限公司 |
B7-h3纳米抗体、其制备方法及用途
|
|
CN114929748A
(zh)
*
|
2019-11-18 |
2022-08-19 |
得克萨斯州大学系统董事会 |
抗b7-h3单克隆抗体及其使用方法
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
IL294879A
(en)
|
2020-01-29 |
2022-09-01 |
Inhibrx Inc |
Monodomain antibodies of cd28 and their multivalent and multispecific constructs
|
|
EP4138931A1
(en)
*
|
2020-04-24 |
2023-03-01 |
Y-Mabs Therapeutics, Inc. |
B7h3 antibodies with chelators
|
|
US20230312721A1
(en)
*
|
2020-06-04 |
2023-10-05 |
Y-Mabs Therapeutics, Inc. |
Anti-B7H3 Antibodies for the Treatment of Cancer
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
EP4172323A1
(en)
|
2020-06-29 |
2023-05-03 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
CN112851812B
(zh)
|
2020-06-30 |
2021-09-14 |
广州百暨基因科技有限公司 |
抗b7h3抗体及其应用
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
JP2024500512A
(ja)
*
|
2020-12-23 |
2024-01-09 |
イノベント バイオロジクス（シンガポール）プライベート リミティド |
抗ｂ７－ｈ３抗体およびその使用
|
|
CN119504997A
(zh)
|
2021-02-09 |
2025-02-25 |
苏州宜联生物医药有限公司 |
生物活性物偶联物及其制备方法和用途
|
|
US20220325287A1
(en)
|
2021-03-31 |
2022-10-13 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
WO2022251253A1
(en)
|
2021-05-24 |
2022-12-01 |
Provention Bio, Inc. |
Methods for treating type 1 diabetes
|
|
KR20240026507A
(ko)
|
2021-06-29 |
2024-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
|
|
EP4401836A1
(en)
*
|
2021-09-18 |
2024-07-24 |
Skyline Therapeutics Limited |
Aav for the gene therapy of wet-amd
|
|
WO2023060137A2
(en)
*
|
2021-10-05 |
2023-04-13 |
Board Of Regents, The University Of Texas System |
Methods and compositions comprising b7-h3 binding polypeptides
|
|
US20250092140A1
(en)
*
|
2022-01-14 |
2025-03-20 |
Shenghe (China) Biopharmaceutical Co., Ltd. |
Bispecific antibody binding to b7h3 and nkp30, and application thereof
|
|
WO2023155808A1
(zh)
|
2022-02-16 |
2023-08-24 |
苏州宜联生物医药有限公司 |
抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
|
|
AU2023236289A1
(en)
|
2022-03-15 |
2024-08-15 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
|
CN116836281A
(zh)
*
|
2022-03-25 |
2023-10-03 |
英诺湖医药(杭州)有限公司 |
B7h3抗体及包含其的双功能抗体
|
|
WO2023221975A1
(zh)
|
2022-05-18 |
2023-11-23 |
苏州宜联生物医药有限公司 |
包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
|
|
AU2023273853A1
(en)
*
|
2022-05-18 |
2024-10-24 |
WuXi Biologics Ireland Limited |
Anti-b7h3 antibody and uses thereof
|
|
US20260055188A1
(en)
*
|
2022-08-19 |
2026-02-26 |
Shenghe (China) Biopharmaceutical Co., Ltd. |
Bispecific antibody and use thereof
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
CN115819608A
(zh)
*
|
2022-10-08 |
2023-03-21 |
盛禾(中国)生物制药有限公司 |
一种纯化融合蛋白的方法
|
|
CN115845047A
(zh)
*
|
2022-11-07 |
2023-03-28 |
盛禾(中国)生物制药有限公司 |
一种异源二聚体蛋白质组合物
|
|
WO2024106939A1
(ko)
*
|
2022-11-15 |
2024-05-23 |
주식회사 셀랩메드 |
B7-h3에 특이적으로 결합하는 항체
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025129565A1
(zh)
*
|
2023-12-21 |
2025-06-26 |
西湖实验室(生命科学和生物医学浙江省实验室) |
一种cd276迷你结合蛋白及其突变体及应用
|
|
WO2025245264A1
(en)
*
|
2024-05-21 |
2025-11-27 |
Briapro Therapeutics Corp. |
Anti-b7-h3 antibodies and methods of use thereof
|